All In MedTech

Indication · Cardiology

Stroke prevention in atrial fibrillation

Devices FDA has cleared or approved since 2000 for stroke prevention in atrial fibrillation, found through the 4 FDA device types (product codes) used for it, plus device trials and research. Also searched as: left atrial appendage, stroke prevention atrial fibrillation.

Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov

Devices

52

Cleared or approved since 2000

PMA and De Novo

6

Higher-risk or first-of-kind devices

Breakthrough devices

0

Authorized through June 30, 2026

Recruiting device trials

29

159 device trials in all

Devices

1 devices via De Novo. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.

AllPMADe Novo510(k)
  • HemosIL Liquid Anti-Xa

    Instrumentation Laboratory CO · De Novo · Anti-Factor Xa Activity Test System, Apixaban · newest 2023 · 2 decisions

Device trials

Device studies on ClinicalTrials.gov for this condition, any status, newest update first.

Open in Trial Radar
  • Boston Scientific CorporationPublic (BSX)

    NCT07287436 · 400 participants (planned) · Start Sep 18, 2026 · Primary completion Jan 2028

    Device: WATCHMAN Elite LAAC Device · For: Atrial Fibrillation (AF); Stroke

    Sites: Jonesboro, Arkansas; Santa Monica, California; Rochester, Minnesota · 5 sites in all

158 more trials with a free account

Device types

FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.

Research

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.